A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Status:
RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.